Biocon’s contract research arm -- Syngene International -- has expanded its ongoing drug discovery and development with US-based Bristol-Myers Squibb till 2026. The expanded scope of partnership also includes addition of a new facility and ramping up the team of scientists working for it. The next phase of the partnership will see the addition of a new facility to support future Bristol-Myers Squibb research and development operations.
As part of the expansion, Syngene will set up a new dedicated facility spread across 25,000 sq ft of laboratory and office space for Bristol-Myers Squibb. This facility will house an additional team of 75 Syngene scientists who will work exclusively for Bristol-Myers Squibb.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
